



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company
CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2019-20

14th August, 2019

Online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Dalal Street, Fort,
MUMBAI-400001

BSE CODE: 524470

Subject: Submission of the Standalone Unaudited Financial Results and Limited Review Report of the Auditors for the Quarter ended 30th June, 2019 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am,

This is in continuation of our letter No. SYNCOM/SE/2019-20 dated 1st August, 2019 regarding intimation of Board meeting for consideration and approval of the Quarterly Standalone Un-audited Financial Results & Limited Review Report thereon, for the Quarter Ended 30th June, 2019.

We are pleased to submit the followings;

1. Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2019 which was considered and approved by the Board at their Meeting held on 14th August, 2019 in accordance with the Regulation 33 of the SEBI (LODR) Regulations, 2015.
2. Limited Review Report given by the Auditors on the Standalone Unaudited Financial Results of the Company for the Quarter Ended 30th June, 2019 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, which was also considered and approved by the Audit Committee and Board of Directors of the Company at their meeting held on 14th August, 2019.


We are also in process of filing the aforesaid Financial Results in the XBRL format within the stipulated time and the same shall also be hosted at the website of the Company.

The Financial Results will be published in widely circulated English and Marathi Newspapers in the prescribed format.

You are requested to take on record the above said Standalone Un-audited Financial Results & Limited Review Report for your reference and record.

Thanking You,
Yours Faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED


CS SHUBHAM DUBEY
COMPANY SECRETARY &
COMPLIANCE OFFICER



Encl.: Standalone Unaudited Financial Results and Limited Review Report.

Bringing a smile on every face...



SYNCOM FORMULATIONS (INDIA) LIMITED

REGD. OFF.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI-400 093

WORKS : 256-257, Sector-1, Pithampur (Dhar), E-mail: info@sfil.in - CIN: L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2019

S. No.	Particulars (Rs. in Lakhs Except EPS)	Quarter Ended		Year Ended 31.03.2019 (Audited)
		30.06.2019 (Unaudited)	31.03.2019 (Audited)	
1	Income from Operations			
	(a) Net sales	5383.92	6124.00	18677.23
	(b) Other Income	139.76	135.77	508.08
2	Total Income	5523.68	6259.77	19185.31
3	Expenses			
	(a) Cost of Material Consumed	2662.91	1924.35	8161.80
	(b) Purchase of stock in trade	1919.36	2599.86	5504.42
	(c) Changes in inventories of finished goods, Work in progress and stock in trade	(594.55)	340.17	(246.25)
	(d) Employee Benefit Expenses	392.93	417.04	364.83
	(e) Finance Cost	4.40	6.03	21.88
	(f) Depreciation and amortization Expenses	100.41	101.23	99.39
	(g) Other Expenses	623.24	555.21	464.96
	Total Expenses (4)	5114.70	5943.89	3227.81
4	Profit/ (loss) before exceptional item and tax (3-4)	408.98	315.87	1909.09
5	Exceptional Items	0.00	0.00	0.00
6	Profit before tax (5-6)	408.98	315.87	1909.09
7	Tax Expenses			
	(a) Current Tax	107.60	91.10	40.00
	(b) Deferred Tax	4.48	4.49	(55.00)
	Total Tax Expenses	112.08	95.59	(15.00)
8	Profit/ (loss) for the period from continuing operations (7-8)	296.90	220.28	205.09
9	Profit/ (loss) for the period from continuing operations (7-8)			
	(a) Profit/ (loss) from continuing operations	0.00	0.00	0.00
	(b) Tax Expenses of discontinuing Operations (after Tax)	0.00	0.00	0.00
	(c) Profit/ (loss) for the period from Discontinuing operations (after Tax) (10-11)	0.00	0.00	0.00
10	Profit/ (loss) for the period (9+12)	296.90	220.28	205.09
11	Other Comprehensive Income:			
	(i) Items that will not be reclassified to P&L	0.00	0.00	0.00
	(ii) Income Tax relating to items that will not be reclassified to Profit & Loss	(23.77)	25.08	(28.39)
	Total Comprehensive Income for the period (14+15)	273.13	245.36	108.70
12	Paid up Equity Capital	7806.52	7806.52	7806.52
13	Other Equity			
	(a) Basic	0.03	0.03	0.02
	(b) Diluted	0.03	0.03	0.02
14	Earning Per Share (of Rs. 1/- each) for continuing Operations			
	(a) Basic	0.03	0.03	0.02
	(b) Diluted	0.03	0.03	0.02
15	Earning Per Share (of Rs. 1/- each) for Dis-continuing Operations			
	(a) Basic	0.03	0.03	0.02
	(b) Diluted	0.03	0.03	0.02

SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS

S. No.	Particulars (Rs. in Lakhs)	Quarter Ended			Year Ended 31.03.2019 (Audited)
		30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Unaudited)	
1	Segment Revenue				
	(a) Pharmaceuticals Drugs & Formulations	3819.65	4509.82	2951.47	14644.87
	(b) Trading of Commodities	1613.68	1654.97	382.23	4187.97
	(c) Renting of Property	90.35	94.98	84.20	352.47
	Total	5523.68	6259.77	3417.90	19185.31
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00
	Net Sales/Income from Operations	5523.68	6259.77	3417.90	19185.31
2	Segment Results (Profit/Loss(-) before tax and interest from each Segment				
	(a) Pharmaceuticals Drugs & Formulations	287.03	225.52	98.45	878.48
	(b) Trading of Commodities	36.00	1.40	13.89	58.48
	(c) Renting of Property	90.35	94.98	84.20	352.47
	Total	413.38	321.90	196.54	1289.43
	Less: (i) Interest	4.40	6.03	6.45	21.88
	(ii) Other Un-allocable Expenditure (net off Un-allocable Income)	0.00	0.00	0.00	0.00
	Total Profit Before Tax	408.98	315.87	190.09	1267.55
3	(Segment Assets - Segment Liabilities)				
	Segment Assets				
	(a) Pharmaceuticals Drugs & Formulations	13002.66	12720.68	11934.47	12720.68
	(b) Trading of Commodities	487.26	515.13	103.45	515.13
	(c) Renting of Property	4087.55	4065.57	4046.07	4065.57
	Total Segment Assets	17577.47	17301.38	16083.99	17301.38
	Unallocable Assets	0.00	0.00	0.00	0.00
	Net Segment Assets	17577.47	17301.38	16083.99	17301.38
	Segment Liabilities				
	(a) Pharmaceuticals Drugs & Formulations	3904.17	3860.02	3580.31	3860.02
	(b) Trading of Commodities	5.30	52.33	4.17	52.33
	(c) Renting of Property	132.48	122.99	128.55	122.99
	Total Segment Liabilities	4041.95	4035.34	3713.03	4035.34
	Unallocable Liabilities	0.00	0.00	0.00	0.00
	Net Segment Liabilities	4041.95	4035.34	3713.03	4035.34

Notes:

- The above results were reviewed by the Auditor & Approved by Audit Committee and thereafter have been adopted by the Board at its meeting held on 14.08.2019.
- The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended.
- The company is operating in three segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities and (c) Renting of property, particulars for segment wise results are as above.
- Effective from 1st April, 2019, the company has adopted Indian Accounting Standards (IND AS) 116 "Leases", using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2019 and there was no material impact on financial results for the quarter ended on 30th June, 2019.
- Previous period figures have been regrouped/reclassified where necessary to conform to this period classification.
- The figure of last quarter ended on 31.03.2019 is not performing figures. The above figures have been audited figures in respect of full financial year.

By order of The Board of Directors
for SYNCOM FORMULATIONS (INDIA) LIMITED
Kedarnal Bankia
Chairman & Whole-Time Director
DIN : 00023050

Place : Indore
Dated : 14/08/2019

SANJAY MEHTA & ASSOCIATES

Chartered Accountants

338, Saket Nagar, Indore - 452 018

Phone/Telefax : 0731-4274391, 2563625

E-mail:sanjaymehta.associates@gmail.com

Limited Review Report

TO,
THE BOARD OF DIRECTORS OF
SYNCOM FORMULATIONS (INDIA) LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of Syncom Formulations (India) Limited for the period ended 30th June, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: 14/08/2019

For, Sanjay Mehta & Associates
Chartered Accountants

FRN: 011524C

CA Manish Mittal
(Partner)

M. No. 079452

UDIN: 19079452AAAAGT5594

